Staphylococcus aureus News and Research

RSS

Staphylococcus aureus is a spherical bacterium (coccus) which on microscopic examination appears in pairs, short chains, or bunched, grape-like clusters. These organisms are Gram-positive. Some strains are capable of producing a highly heat-stable protein toxin that causes illness in humans.

Fero Industries to complete acquisition of Pyro Pharmaceuticals by November 30, 2009

Fero Industries, Inc. is pleased to provide certain disclosures relating to the ten pending patent applications of Pyro Pharmaceuticals, Inc. As previously announced, the Company has initiated the process of acquiring Pyro Pharmaceuticals, Inc. through an exchange of Pyro’s capital stock for shares of the Company’s common stock, with Fero remaining as the parent entity and Pyro as a subsidiary. The acquisition of Pyro is expected to close by November 30, 2009.

27 Oct 2009

Multiple programs and strategies to improve patient safety presented

Kathy Donohue, R.N. of Independence Blue Cross (IBC), will present on a patient safety panel as part of the Pennsylvania State Nurses Summit this morning at 10:30 a.m. at DeSales University in the Lehigh Valley.

24 Oct 2009

BD to acquire HandyLab

BD (Becton, Dickinson and Company)announced today that it signed a definitive agreement to acquire HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms. The acquisition is subject to regulatory approvals and is expected to close during the first quarter of fiscal year 2010. The financial terms of the agreement were not disclosed.

From BD (Becton, Dickinson and Company) 24 Oct 2009

HHS funds $17M for fight against costly and dangerous health care-associated infections

HHS Secretary Kathleen Sebelius today announced the award of $17 million to fund projects to fight costly and dangerous health care-associated infections, or HAIs.

24 Oct 2009

Theravance earns milestone payment for bactericidal, injectable lipoglycopeptide antibiotic

Theravance, Inc. announced today that it has earned a milestone payment of $20 million for the U.S. Food and Drug Administration (FDA) approval of VIBATIV (telavancin) and supplying its collaboration partner, Astellas Pharma US, Inc. (Astellas), with the launch inventory for the first commercial sale in the United States.

23 Oct 2009

Winner of first annual Healthcare Administrator Award announced

Deborah Friberg, Chief Operating Officer and Executive Vice President of WakeMed Health and Hospitals, Raleigh, North Carolina, has been named the recipient of the first annual Healthcare Administrator Award, presented by the Association for Professionals in Infection Control and Epidemiology (APIC). The award recognizes a healthcare facility's executive team member who has demonstrated significant support for infection prevention and control throughout their facility.

20 Oct 2009

Study on the economic impact of antibiotic overuse and antibiotic-resistant infections

The Alliance for the Prudent Use of Antibiotics (APUA) and Cook County Hospital (currently John H. Stroger, Jr. Hospital of Cook County), today announced the release of an eye-opening study on the economic impact of antibiotic overuse and antibiotic-resistant infections (ARIs) sponsored by an unrestricted educational grant from bioMerieux and the Centers for Disease Control and Prevention (CDC).

19 Oct 2009

TheraDoc commences beta testing of new computerized patient surveillance tool

TheraDoc®, the leading provider of clinical decision support technology in healthcare, today announced that it has started beta testing of a new computerized patient surveillance tool that will help hospitals monitor and manage screening programs for multidrug-resistant organisms (MDROs), such as methicillin-resistant Staphylococcus aureus, or MRSA, which every year kills more people in the United States than AIDS.

19 Oct 2009

Fero Industries to acquire Pyro Pharmaceuticals

Fero Industries, Inc. (the “Company”) is pleased to announce that the Company has entered into a Definitive Agreement to acquire Pyro Pharmaceuticals, Inc. of Irvine, California.

15 Oct 2009

Harvard researchers unite in fight against antibiotic resistance

The National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) have awarded $5 million to an interdisciplinary group of Harvard researchers to launch the "Harvard-wide Program on Antibiotic Resistance."

14 Oct 2009

Pennsylvania Patient Safety Authority's initiative to raise awareness of healthcare-associated infections

The Pennsylvania Patient Safety Authority supports "International Infection Prevention Week," October 18-24, 2009, to raise awareness of the need to protect patients and the public from healthcare-associated infections (HAIs).

14 Oct 2009

TAXIS Pharmaceuticals, Rutgers and UMDNJ to develop and commercialize a novel antimicrobial technology

TAXIS Pharmaceuticals, Inc. (TAXIS), Rutgers, The State University of New Jersey, and the University of Medicine and Dentistry of New Jersey (UMDNJ) have entered into an exclusive licensing agreement for worldwide rights to develop and commercialize a novel antimicrobial technology addressing multidrug-resistant (MDR) bacterial infections.

14 Oct 2009

Paratek Pharmaceuticals and Novartis to collaborate in PTK 0796 broad-spectrum antibiotic development

Paratek Pharmaceuticals, Inc. announced today that it has entered into an exclusive worldwide collaborative development, manufacturing and commercialization license agreement with Novartis for Paratek's lead broad-spectrum antibiotic, PTK 0796, a first-in-class aminomethylcycline (AMC) in Phase 3 clinical trials.

8 Oct 2009

Report on the worldwide market for anti-infectives

Drug resistance is a key public health problem and also a problem for makers of branded antibacterial products, according to the findings of a new report. Traditional antibiotics: quinolones, cephalosporins, and penicillins, have seen their market share erode due to loss of effectiveness, while at the same time they are facing heavy generic competition.

3 Oct 2009

Health Canada approves VIBATIV for treating complicated skin and skin structure infections

Astellas Pharma Canada, Inc. announced today that Health Canada has approved VIBATIV(TM) (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

1 Oct 2009

Automated SafetySurveillor system to detect healthcare-associated infections

The Premier healthcare alliance today announced that Bon Secours St. Francis Medical Center of Midlothian, Va., selected Premier’s SafetySurveillor® Web-based infection tracking and antimicrobial utilization tool. More than 270 hospitals use SafetySurveillor to help prevent healthcare-associated infections (HAIs) and optimize antibiotic use, thereby protecting patients more effectively while safely reducing hospital costs.

30 Sep 2009

PolyMedix receives patent protection for computational methods in the design of amphiphilic polymers

PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has received patent protection for certain exclusively licensed intellectual property by the issuance to the University of Pennsylvania of U.S. patent number 7,590,517, “Methods, Systems, and Computer Program Products for Computational Design of Amphiphilic Polymers.”

28 Sep 2009

Micro Imaging announces the settlement with Divine Capital regarding issuance of convertible debentures

Micro Imaging Technology, Inc. has announced that it and Divine Capital Markets, LLC have settled all claims and counterclaims asserted in a lawsuit pending in New York State Supreme Court arising from the issuance of convertible debentures.

25 Sep 2009

ONA appeals against Ministry of Labour's decision in London nurse's death investigation

The Ontario Nurses' Association (ONA) is appealing the decision by a Ministry of Labour inspector to not issue orders against London Health Sciences Centre or make recommendations for improvements in procedures and practices following the death of one of its registered nurses of methicillin-resistant staphylococcus aureus (MRSA).

22 Sep 2009

Biochemists are developing a new system to better understand antibiotic resistance

Rice University biochemists are developing a system of "evolutionary forecasting" to better understand the mechanisms of antibiotic resistance.

22 Sep 2009

Staphylococcus aureus News and Research

Further Reading

Fero Industries to complete acquisition of Pyro Pharmaceuticals by November 30, 2009

Multiple programs and strategies to improve patient safety presented

BD to acquire HandyLab

HHS funds $17M for fight against costly and dangerous health care-associated infections

Theravance earns milestone payment for bactericidal, injectable lipoglycopeptide antibiotic

Winner of first annual Healthcare Administrator Award announced

Study on the economic impact of antibiotic overuse and antibiotic-resistant infections

TheraDoc commences beta testing of new computerized patient surveillance tool

Fero Industries to acquire Pyro Pharmaceuticals

Harvard researchers unite in fight against antibiotic resistance

Pennsylvania Patient Safety Authority's initiative to raise awareness of healthcare-associated infections

TAXIS Pharmaceuticals, Rutgers and UMDNJ to develop and commercialize a novel antimicrobial technology

Paratek Pharmaceuticals and Novartis to collaborate in PTK 0796 broad-spectrum antibiotic development

Report on the worldwide market for anti-infectives

Health Canada approves VIBATIV for treating complicated skin and skin structure infections

Automated SafetySurveillor system to detect healthcare-associated infections

PolyMedix receives patent protection for computational methods in the design of amphiphilic polymers

Micro Imaging announces the settlement with Divine Capital regarding issuance of convertible debentures

ONA appeals against Ministry of Labour's decision in London nurse's death investigation

Biochemists are developing a new system to better understand antibiotic resistance

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News